Please login to the form below

Not currently logged in
Email:
Password:

antisense drugs

This page shows the latest antisense drugs news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Akcea’s rare inherited disorder drug Waylivra

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Waylivra (volanesorsen) is an antisense drugs, used for the treatment of a rare inherited disorder called familial chylomicronemia syndrome (FCS). ... The FDA had concerns about the drug’s safety, particularly fears surrounding some reductions in blood

Latest news

  • ‘Missing protein’ biotech Stoke raises $142m in IPO ‘Missing protein’ biotech Stoke raises $142m in IPO

    Stoke’s therapeutic approach – called TANGO - is based on antisense drugs that are used to up-regulate the production of messenger RNA, which in turn produce proteins. ... The biotech says its antisense drugs can increase the levels of functional mRNA

  • ‘Missing protein’ biotech Stoke raises $142m in IPO

    Stoke’s therapeutic approach – called TANGO - is based on antisense drugs that are used to up-regulate the production of messenger RNA, which in turn produce proteins. ... The biotech says its antisense drugs can increase the levels of functional mRNA

  • Twentyeight-Seven raises another $15m for non-coding RNA drugs Twentyeight-Seven raises another $15m for non-coding RNA drugs

    in the US – and is based on the use of small-molecule drugs targeting ncRNA modulating proteins (RMPs) in order to affect the expression of disease-associated proteins. ... This is a different approach to the emerging class of RNA therapeutics that

  • Ionis and Roche gain PRIME status for Huntingdon’s disease candidate Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

    The company specialises in antisense drugs, which ‘silence’ RNA and target diseases much closer to their genetic origins than conventional therapies. ... He added: "This is our second antisense drug to demonstrate a strong safety profile and

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    have focused on RNA and oligonucleotide-based drugs to switch off the activity of problem genes and gene-editing using CRISPR technology, rather than vector-based gene transfer. ... also working with Ionis on antisense drugs for a range of targets

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    510. Isis. Antisense drugs for CVS metabolic and renaldisease. 65. Mirati Therapeutics. ... Exclusive licence. 90. Isis. AZ. Addition to Dec 2012 collaboration to develop antisense drugs in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Strategic collaboration. 1, 000. Isis/ Janssen. Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes).

  • Pharma deals during January 2015 Pharma deals during January 2015

    A $35m payment went in an upfront to Isis as part of its $835m headline deal for a collaboration to discover and develop antisense drugs in autoimmune disorders in the GI ... tract. The deal includes options to license drugs arising from the various

  • Pharma deals during December 2012 Pharma deals during December 2012

    an upfront of $30m, to discover and co-develop antisense drugs to treat three neurological or neuromuscular disorders. In January 2012, Biogen Idec paid Isis an upfront of $29m for an ... 231. Isis / Biogen. Co-development and option to licence.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics